Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Development of AS-1403 discontinued following phase I biodistribution results

Aug. 27, 2003

German permits for 1D09C3 pave way for E.U. clinical trials

Aug. 26, 2003

Intravesical rhIL-12 in recurrent STCC of the bladder

Aug. 20, 2003

SGN-35 selectively targets CD30-positive malignancies in models of Hodgkin's disease

Aug. 13, 2003

Scancell and Celltech collaborate on antibody therapeutics to Lewis(y/b)

Aug. 11, 2003

GPC Biotech makes progress on various fronts with 1D09C3

Aug. 6, 2003

Grant supports development of cancer vaccines at Epimmune using analogue epitopes

Aug. 1, 2003

Phase II trial indicates promising efficacy for alemtuzumab in MF/SS

July 31, 2003

Anti-gp75 antibodies evaluated as potential therapies for melanoma

July 25, 2003

BMS evaluates the potential of agonist antibodies targeting CD137 for antitumor therapy

July 24, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....